AstraZeneca's Truqap Receives Strong FDA Advisory Committee Support for Prostate Cancer Treatment

An FDA independent advisory committee has voted overwhelmingly in favor of using Truqap as a combination therapy for prostate cancer. The 7-1 decision signals a high probability of formal FDA approval for the anti-tumor agent.

• FDA advisory committee recommended Truqap for prostate cancer
• Committee voted 7-1 in favor of the drug
• Truqap (capivasertib) is an anti-tumor agent
• Approval would expand AstraZeneca's oncology portfolio
• AdCom votes are highly predictive of final FDA decisions